Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
630.00    -3.00 (-0.47%)
Bid:
629.00
Ask:
633.00
Spread: 4.00 (0.636%)
Market Cap: £548.88m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Update

7 Apr 2011 07:00

RNS Number : 4485E
Victrex PLC
07 April 2011
 



For Stock Exchange release at 7.00 a.m. Thursday 7 April 2011

Victrex plc

 

Half Year Trading Update

 

The Company announces its trading update for the six months ended 31 March 2011.

 

We are pleased to announce a record half year Group sales volume of approximately 1,434 tonnes, an increase of 22% over the first half of the previous financial year (1,171 tonnes). The record 752 tonnes sold in the second quarter of this year was 10% above the 682 tonnes sold in the first quarter, reinforcing the positive underlying trends in the Victrex Polymer Solutions business.

 

Despite continuing uncertain market conditions in the US, Invibio®, our biomaterial solutions business, delivered record half year revenue ofapproximately £24.3m, an increase of 10% over the first half of the previous financial year (£22.1m). The potential opportunities for Invibio in new market areas and geographies remain strong.

 

Victrex will announce its results for the six months ended 31 March 2011 on Tuesday 24 May 2011.

 

Enquiries

 

Victrex plc

Peter Bream, Finance Director 0203 128 8100 (7 April 2011)

01253 897 700 (thereafter)

 

MHP Communications

Nick Denton / Barnaby Fry / Ian Payne 0203 128 8100

 

 

Victrex plc is an innovative world leader in high performance materials through the manufacture of VICTREX® PEEK™ polymer, a high performance, easy to process thermoplastic.

 

With over 30 years of experience, Victrex is a global manufacturer of innovative, high performance thermoplastic polymers. We work with customers and end users to deliver technology driven solutions to the challenges and opportunities they face. Our Victrex Polymer Solutions division ('VPS') focuses on our transport, industrial and electronics markets and our Invibio Biomaterial Solutions division ('Invibio') focuses on providing specialist solutions for medical device manufacturers.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEQLFBFZFZBBV
Date   Source Headline
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding
31st Jul 202412:20 pmRNSTotal Voting Rights
5th Jul 20242:02 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSQ3 Interim Management Statement
28th Jun 20249:52 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.